arrow
B

Bob W. van Oosten

vrije universiteit amsterdam
H指数:31
被引数:5,616

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis

多发性硬化患者个性化延长间隔给药方案下纳武利尤单抗的治疗满意度

2026-07-010
PRE
Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS) – an Individual Participant Data Meta-Analysis

利妥昔单抗相较于奥瑞珠单抗在多发性硬化中的非劣效性(ROC-MS)——一项个体参与者数据meta分析

2025-11-110
OAAI
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)

血清神经丝蛋白轻链和胶质纤维酸性蛋白在稳定型多发性硬化(DOT-MS)中停用一线疾病修饰疗法后检测疾病活动的可靠性

2025-07-230
OAAI
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
2025-03-010
PRE
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
2024-11-041
OAAI
Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic
2024-10-171
OAAI
Influence of personalized extended interval dosing on the natalizumab wearing-off effect- a sub-study of the NEXT-MS trial
2024-07-010
OAAI
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
2023-11-147
OA
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis
2023-01-138
OA